Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution
Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 t...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2013-11, Vol.92 (11), p.1529-1536 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1536 |
|---|---|
| container_issue | 11 |
| container_start_page | 1529 |
| container_title | Annals of hematology |
| container_volume | 92 |
| creator | Yu, Jui-Ting Wang, Chen-Yu Yang, Youngsen Wang, Ren-Ching Chang, Kuang-Hsi Hwang, Wen-Li Teng, Chieh-Lin Jerry |
| description | Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Patients were divided into B cell (
n
= 13) and T cell (
n
= 17) lymphoma groups. Patients’ age, performance status, presence of Epstein–Barr virus infection, international prognostic index, presence of disseminated intravascular coagulopathy, serum triglyceride, fibrinogen, and lactate dehydrogenase levels were not significantly different between B cell and T cell lymphoma groups. HLH was an indicator for treatment resistance in patients with B cell (
p
= 0.048), but not T cell (
p
= 0.217), lymphoma. Patients in the T cell lymphoma group, however, had higher serum ferritin levels than patients in the B cell lymphoma group (11,525.6 versus 3,790.6 ng/mL;
p
= 0.043). The median survival time for patients in the B cell and T cell lymphoma groups was 330 and 96 days, respectively. Although the difference was not statistically significant (
p
= 0.273), our results suggested a trend toward a better overall survival time in patients with B cell lymphoma. This survival advantage could be at least partially due to use of rituximab (
p
= 0.045) for the treatment of patients with B cell lymphoma. Our results also suggested that allogeneic hematopoietic stem cell transplantation could possibly provide survival benefits to T cell lymphoma-associated HLH by graft-versus-lymphoma effect. |
| doi_str_mv | 10.1007/s00277-013-1784-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443400661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089481191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-7b882e36a8dd1af18c37717bd9ce7c286c7d79766f7adcfa29f45e682af1275e3</originalsourceid><addsrcrecordid>eNp1kc1q3DAURkVpaSZJHyCbYOimGyX6G0nOroQ2CQxk06yFRr6eUbAtR9eGzttX7iSlFKqN4OqcT0IfIRecXXHGzDUyJoyhjEvKjVVUviMrrqSgbG3Ve7JitazpuqwTcor4zBgXVomP5ERIU1TLVqTdHPpxn3pPPWIK0U_QVHvo07j3uxQOUwxV9xvZR5ziMkkY8aaCnyPkCEOAKg6Vb-ZuwqrNqa98hXHYdcu8GNNcrOGcfGh9h_DpdT8jT9-__bi9p5vHu4fbrxsalLQTNVtrBUjtbdNw33IbpDHcbJs6gAnC6mAaUxutW-Ob0HpRt2oN2orCCrMGeUa-HHPHnF5mwMn1EQN0nR8gzei4UlIxpjUv6Od_0Oc056G8rlCyFppptlD8SIWcEDO0bsyx9_ngOHNLCe5YgiusW0pwsjiXr8nztofmj_H26wUQRwDL0bCD_NfV_039BSuvk_M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1439260601</pqid></control><display><type>article</type><title>Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Yu, Jui-Ting ; Wang, Chen-Yu ; Yang, Youngsen ; Wang, Ren-Ching ; Chang, Kuang-Hsi ; Hwang, Wen-Li ; Teng, Chieh-Lin Jerry</creator><creatorcontrib>Yu, Jui-Ting ; Wang, Chen-Yu ; Yang, Youngsen ; Wang, Ren-Ching ; Chang, Kuang-Hsi ; Hwang, Wen-Li ; Teng, Chieh-Lin Jerry</creatorcontrib><description>Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Patients were divided into B cell (
n
= 13) and T cell (
n
= 17) lymphoma groups. Patients’ age, performance status, presence of Epstein–Barr virus infection, international prognostic index, presence of disseminated intravascular coagulopathy, serum triglyceride, fibrinogen, and lactate dehydrogenase levels were not significantly different between B cell and T cell lymphoma groups. HLH was an indicator for treatment resistance in patients with B cell (
p
= 0.048), but not T cell (
p
= 0.217), lymphoma. Patients in the T cell lymphoma group, however, had higher serum ferritin levels than patients in the B cell lymphoma group (11,525.6 versus 3,790.6 ng/mL;
p
= 0.043). The median survival time for patients in the B cell and T cell lymphoma groups was 330 and 96 days, respectively. Although the difference was not statistically significant (
p
= 0.273), our results suggested a trend toward a better overall survival time in patients with B cell lymphoma. This survival advantage could be at least partially due to use of rituximab (
p
= 0.045) for the treatment of patients with B cell lymphoma. Our results also suggested that allogeneic hematopoietic stem cell transplantation could possibly provide survival benefits to T cell lymphoma-associated HLH by graft-versus-lymphoma effect.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-013-1784-3</identifier><identifier>PMID: 23700280</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Cohort Studies ; Female ; Follow-Up Studies ; Hematology ; Humans ; Lymphohistiocytosis, Hemophagocytic - diagnosis ; Lymphohistiocytosis, Hemophagocytic - mortality ; Lymphohistiocytosis, Hemophagocytic - therapy ; Lymphoma, B-Cell - diagnosis ; Lymphoma, B-Cell - mortality ; Lymphoma, B-Cell - therapy ; Lymphoma, T-Cell - diagnosis ; Lymphoma, T-Cell - mortality ; Lymphoma, T-Cell - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Retrospective Studies ; Young Adult</subject><ispartof>Annals of hematology, 2013-11, Vol.92 (11), p.1529-1536</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-7b882e36a8dd1af18c37717bd9ce7c286c7d79766f7adcfa29f45e682af1275e3</citedby><cites>FETCH-LOGICAL-c438t-7b882e36a8dd1af18c37717bd9ce7c286c7d79766f7adcfa29f45e682af1275e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-013-1784-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-013-1784-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23700280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Jui-Ting</creatorcontrib><creatorcontrib>Wang, Chen-Yu</creatorcontrib><creatorcontrib>Yang, Youngsen</creatorcontrib><creatorcontrib>Wang, Ren-Ching</creatorcontrib><creatorcontrib>Chang, Kuang-Hsi</creatorcontrib><creatorcontrib>Hwang, Wen-Li</creatorcontrib><creatorcontrib>Teng, Chieh-Lin Jerry</creatorcontrib><title>Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Patients were divided into B cell (
n
= 13) and T cell (
n
= 17) lymphoma groups. Patients’ age, performance status, presence of Epstein–Barr virus infection, international prognostic index, presence of disseminated intravascular coagulopathy, serum triglyceride, fibrinogen, and lactate dehydrogenase levels were not significantly different between B cell and T cell lymphoma groups. HLH was an indicator for treatment resistance in patients with B cell (
p
= 0.048), but not T cell (
p
= 0.217), lymphoma. Patients in the T cell lymphoma group, however, had higher serum ferritin levels than patients in the B cell lymphoma group (11,525.6 versus 3,790.6 ng/mL;
p
= 0.043). The median survival time for patients in the B cell and T cell lymphoma groups was 330 and 96 days, respectively. Although the difference was not statistically significant (
p
= 0.273), our results suggested a trend toward a better overall survival time in patients with B cell lymphoma. This survival advantage could be at least partially due to use of rituximab (
p
= 0.045) for the treatment of patients with B cell lymphoma. Our results also suggested that allogeneic hematopoietic stem cell transplantation could possibly provide survival benefits to T cell lymphoma-associated HLH by graft-versus-lymphoma effect.</description><subject>Adult</subject><subject>Aged</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lymphohistiocytosis, Hemophagocytic - diagnosis</subject><subject>Lymphohistiocytosis, Hemophagocytic - mortality</subject><subject>Lymphohistiocytosis, Hemophagocytic - therapy</subject><subject>Lymphoma, B-Cell - diagnosis</subject><subject>Lymphoma, B-Cell - mortality</subject><subject>Lymphoma, B-Cell - therapy</subject><subject>Lymphoma, T-Cell - diagnosis</subject><subject>Lymphoma, T-Cell - mortality</subject><subject>Lymphoma, T-Cell - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1q3DAURkVpaSZJHyCbYOimGyX6G0nOroQ2CQxk06yFRr6eUbAtR9eGzttX7iSlFKqN4OqcT0IfIRecXXHGzDUyJoyhjEvKjVVUviMrrqSgbG3Ve7JitazpuqwTcor4zBgXVomP5ERIU1TLVqTdHPpxn3pPPWIK0U_QVHvo07j3uxQOUwxV9xvZR5ziMkkY8aaCnyPkCEOAKg6Vb-ZuwqrNqa98hXHYdcu8GNNcrOGcfGh9h_DpdT8jT9-__bi9p5vHu4fbrxsalLQTNVtrBUjtbdNw33IbpDHcbJs6gAnC6mAaUxutW-Ob0HpRt2oN2orCCrMGeUa-HHPHnF5mwMn1EQN0nR8gzei4UlIxpjUv6Od_0Oc056G8rlCyFppptlD8SIWcEDO0bsyx9_ngOHNLCe5YgiusW0pwsjiXr8nztofmj_H26wUQRwDL0bCD_NfV_039BSuvk_M</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Yu, Jui-Ting</creator><creator>Wang, Chen-Yu</creator><creator>Yang, Youngsen</creator><creator>Wang, Ren-Ching</creator><creator>Chang, Kuang-Hsi</creator><creator>Hwang, Wen-Li</creator><creator>Teng, Chieh-Lin Jerry</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution</title><author>Yu, Jui-Ting ; Wang, Chen-Yu ; Yang, Youngsen ; Wang, Ren-Ching ; Chang, Kuang-Hsi ; Hwang, Wen-Li ; Teng, Chieh-Lin Jerry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-7b882e36a8dd1af18c37717bd9ce7c286c7d79766f7adcfa29f45e682af1275e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lymphohistiocytosis, Hemophagocytic - diagnosis</topic><topic>Lymphohistiocytosis, Hemophagocytic - mortality</topic><topic>Lymphohistiocytosis, Hemophagocytic - therapy</topic><topic>Lymphoma, B-Cell - diagnosis</topic><topic>Lymphoma, B-Cell - mortality</topic><topic>Lymphoma, B-Cell - therapy</topic><topic>Lymphoma, T-Cell - diagnosis</topic><topic>Lymphoma, T-Cell - mortality</topic><topic>Lymphoma, T-Cell - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Jui-Ting</creatorcontrib><creatorcontrib>Wang, Chen-Yu</creatorcontrib><creatorcontrib>Yang, Youngsen</creatorcontrib><creatorcontrib>Wang, Ren-Ching</creatorcontrib><creatorcontrib>Chang, Kuang-Hsi</creatorcontrib><creatorcontrib>Hwang, Wen-Li</creatorcontrib><creatorcontrib>Teng, Chieh-Lin Jerry</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Jui-Ting</au><au>Wang, Chen-Yu</au><au>Yang, Youngsen</au><au>Wang, Ren-Ching</au><au>Chang, Kuang-Hsi</au><au>Hwang, Wen-Li</au><au>Teng, Chieh-Lin Jerry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>92</volume><issue>11</issue><spage>1529</spage><epage>1536</epage><pages>1529-1536</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Patients were divided into B cell (
n
= 13) and T cell (
n
= 17) lymphoma groups. Patients’ age, performance status, presence of Epstein–Barr virus infection, international prognostic index, presence of disseminated intravascular coagulopathy, serum triglyceride, fibrinogen, and lactate dehydrogenase levels were not significantly different between B cell and T cell lymphoma groups. HLH was an indicator for treatment resistance in patients with B cell (
p
= 0.048), but not T cell (
p
= 0.217), lymphoma. Patients in the T cell lymphoma group, however, had higher serum ferritin levels than patients in the B cell lymphoma group (11,525.6 versus 3,790.6 ng/mL;
p
= 0.043). The median survival time for patients in the B cell and T cell lymphoma groups was 330 and 96 days, respectively. Although the difference was not statistically significant (
p
= 0.273), our results suggested a trend toward a better overall survival time in patients with B cell lymphoma. This survival advantage could be at least partially due to use of rituximab (
p
= 0.045) for the treatment of patients with B cell lymphoma. Our results also suggested that allogeneic hematopoietic stem cell transplantation could possibly provide survival benefits to T cell lymphoma-associated HLH by graft-versus-lymphoma effect.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>23700280</pmid><doi>10.1007/s00277-013-1784-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2013-11, Vol.92 (11), p.1529-1536 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1443400661 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Cohort Studies Female Follow-Up Studies Hematology Humans Lymphohistiocytosis, Hemophagocytic - diagnosis Lymphohistiocytosis, Hemophagocytic - mortality Lymphohistiocytosis, Hemophagocytic - therapy Lymphoma, B-Cell - diagnosis Lymphoma, B-Cell - mortality Lymphoma, B-Cell - therapy Lymphoma, T-Cell - diagnosis Lymphoma, T-Cell - mortality Lymphoma, T-Cell - therapy Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Retrospective Studies Young Adult |
| title | Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphoma-associated%20hemophagocytic%20lymphohistiocytosis:%20experience%20in%20adults%20from%20a%20single%20institution&rft.jtitle=Annals%20of%20hematology&rft.au=Yu,%20Jui-Ting&rft.date=2013-11-01&rft.volume=92&rft.issue=11&rft.spage=1529&rft.epage=1536&rft.pages=1529-1536&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-013-1784-3&rft_dat=%3Cproquest_cross%3E3089481191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1439260601&rft_id=info:pmid/23700280&rfr_iscdi=true |